Second biosimilar from Amgen and Allergan approved by FDA

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/psisa)
(Image: Getty/psisa)

Related tags: Amgen, Allergan, Herceptin, Biosimilars, Biologics, Fda, FDA approval, Breast cancer

Amgen’s biosimilars portfolio reaches a milestone after its Herceptin biosimilar, Kanjinti, developed in collaboration with Allergan, was approved by the US FDA.

The US Food and Drug Administration (FDA) approved Kanjinti (trastuzumab-anns) from Amgen and Allergan for all approved indications of the reference drug, Roche’s Herceptin (trastuzumab), including the treatment of HER2-overexpressing adjuvant and metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Kanjinti was approved after demonstrating no clinically meaningful differences to the reference product.

Currently, Kanjinti is the only biosimilar that incorporates the evaluation of a single transition in the clinical study to demonstrate similar safety and immunogenicity in patients who previously received Herceptin.

With this approval, two of the four biosimilars developed per a 2011 collaboration between Amgen and Allergan have received FDA approval. Kanjinti is the 10th approved biosimilar in Amgen’s portfolio, with three drugs approved in the US and three approved in the EU, including Mvasi​ (bevacizumab-awwb) a biosimilar for Roche’s Avastin (bevacizumab).

The collaboration between the two companies sees Amgen responsible for development, manufacturing, and the initial commercialization of the oncology antibody drug candidates, while Allergan provides funding.

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more